Intracellular Biology of Francisella tularensis
Intracellular Biology of Francisella tularensis
批准号:
8260263
负责人:
MARCUS AARON HORWITZ
金额:
$37.31万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-05-01 至 2014-04-30
关键词:
Adenylate CyclaseAntibiotic ResistanceAntibioticsBacteriaBacterial GenesBacterial ProteinsBiologyBioterrorismCathepsinsCell membraneCellsCytoplasmDevelopmentEmerging Communicable DiseasesEngineeringExhibitsFrancisella tularensisGenesGrowthImmunofluorescence ImmunologicImmunofluorescence MicroscopyInfectious Diseases ResearchLibrariesLifeLysosomesMass Spectrum AnalysisMeasuresMembrane GlycoproteinsMembrane Protein TrafficMethodsMicroscopicMorbidity - disease rateMutatePathway interactionsPhagocytosisPhagosomesPhenotypePreventionPrevention strategyProteinsProteomicsRecombinant ProteinsReporterResistanceScreening procedureSiteSmall Interfering RNASystemTechniquesTransmission Electron MicroscopyTularemiaVirulenceVirulentWorkbasebiodefensedesignexpression vectorimprovedkillingsmacrophagemortalitymutantnovel strategiespathogenpreventtooltraffickinguptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Francisella tularensis is a facultative intracellular bacterial pathogen that causes serious and potentially life
threatening illness by surviving and multiplying within host cells, primarily macrophages. Because the
bacterium has extraordinarily high infectivity, causes serious morbidity and mortality, and is easily
dispersed, it is also considered a potential agent of bioterrorism. While currently available antibiotics are
effective in treating tularemia, F. tularensis can be engineered to carry antibiotic resistance genes. For these
reasons, new approaches to treatment and prevention of tularemia are needed. However, devising such
strategies requires an improved understanding of the interaction between F. tularensis and its host cells. We
have demonstrated that fully virulent F. tularensis enter macrophages via spacious pseudopod loops and that
the bacterium then enters a phagosomal compartment that exhibits arrested maturation in that it acquires
limited amounts of lysosome associated membrane glycoproteins, does not acquire cathepsin D, and is only
minimally acidified prior to escape of the bacterium into the macrophage cytoplasm. We propose to define
further the intracellular biology of F. tularensis and to identify the virulence mechanisms that allow it to
evade phagosome-lysososome fusion, phagosome acidification, and to escape into the host cell cytoplasm.
We shall identify host and bacterial proteins that are important to resistance to phagosome-lysosome fusion
and phagosome escape by a mass spectrometry based proteomic comparison of purified phagosomes
containing live wild type F. tularensis, killed F. tularensis, and selected F. tularensis mutants that fail to
escape and that traffic differently within the host cell. We shall identify bacterial genes required for growth in
macrophages that are required for altering the intracellular trafficking and phagosome escape by screening a
transposon mutant library. We shall determine whether specific host and bacterial proteins that we identify
by these methods are required for uptake of the bacteria by looping phagocytosis, resistance to phagosomelysosome
fusion, or phagosome escape by using siRNA techniques and by examining the phenotype of
targeted bacterial mutants by immunofluorescence microscopy and transmission electron microscopy. We
shall determine whether F. tularensis mutants that are defective in phagosome-lysosome fusion or
phagosome escape can be restored to wild-type phenotype by delivering the protein corresponding to the
mutated gene into the host cell cytoplasm or into the F. tularensis phagosome. This will provide information
regarding the possible site of action of these bacterial proteins.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance
-
批准号:10115911
-
项目类别:
-
资助金额:$78.0万
-
财政年份:2021
-
负责人:MARCUS AARON HORWITZ
-
依托单位:
Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance
-
批准号:10372028
-
项目类别:
-
资助金额:$78.0万
-
财政年份:2021
-
负责人:MARCUS AARON HORWITZ
-
依托单位:
Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance
-
批准号:10570976
-
项目类别:
-
资助金额:$78.0万
-
财政年份:2021
-
负责人:MARCUS AARON HORWITZ
-
依托单位:
Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence
-
批准号:10462669
-
项目类别:
-
资助金额:$54.97万
-
财政年份:2020
-
负责人:MARCUS AARON HORWITZ
-
依托单位:
Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence
-
批准号:10120412
-
项目类别:
-
资助金额:$54.97万
-
财政年份:2020
-
负责人:MARCUS AARON HORWITZ
-
依托单位:
Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence
-
批准号:10685383
-
项目类别:
-
资助金额:$54.97万
-
财政年份:2020
-
负责人:MARCUS AARON HORWITZ
-
依托单位:
Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence
-
批准号:10267736
-
项目类别:
-
资助金额:$54.97万
-
财政年份:2020
-
负责人:MARCUS AARON HORWITZ
-
依托单位:
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform
-
批准号:10837445
-
项目类别:
-
资助金额:$15.51万
-
财政年份:2019
-
负责人:MARCUS AARON HORWITZ
-
依托单位:
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform
-
批准号:10308602
-
项目类别:
-
资助金额:$15.51万
-
财政年份:2019
-
负责人:MARCUS AARON HORWITZ
-
依托单位:
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform
-
批准号:9815937
-
项目类别:
-
资助金额:$78.98万
-
财政年份:2019
-
负责人:MARCUS AARON HORWITZ
-
依托单位:
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform
-
批准号:10159194
-
项目类别:
-
资助金额:$77.58万
-
财政年份:2019
-
负责人:MARCUS AARON HORWITZ
-
依托单位:
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform
-
批准号:10642711
-
项目类别:
-
资助金额:$62.07万
-
财政年份:2019
-
负责人:MARCUS AARON HORWITZ
-
依托单位:
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform
-
批准号:10637151
-
项目类别:
-
资助金额:$15.51万
-
财政年份:2019
-
负责人:MARCUS AARON HORWITZ
-
依托单位:
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform
-
批准号:10407621
-
项目类别:
-
资助金额:$62.07万
-
财政年份:2019
-
负责人:MARCUS AARON HORWITZ
-
依托单位:
Optimization and Advanced Proof-of-Concept Studies of a Listeria-vectored Multi-Antigenic Vaccine against Tuberculosis
-
批准号:10308053
-
项目类别:
-
资助金额:$120.07万
-
财政年份:2017
-
负责人:MARCUS AARON HORWITZ
-
依托单位:
Optimization and Advanced Proof-of-Concept Studies of a Listeria-vectored Multi-Antigenic Vaccine against Tuberculosis
-
批准号:10064608
-
项目类别:
-
资助金额:$120.56万
-
财政年份:2017
-
负责人:MARCUS AARON HORWITZ
-
依托单位:
Pre-Exposure Prophylaxis Against Francisella tularensis
-
批准号:8840491
-
项目类别:
-
资助金额:$70.67万
-
财政年份:2013
-
负责人:MARCUS AARON HORWITZ
-
依托单位:
Pre-Exposure Prophylaxis Against Francisella tularensis
-
批准号:8577344
-
项目类别:
-
资助金额:$54.67万
-
财政年份:2013
-
负责人:MARCUS AARON HORWITZ
-
依托单位:
Pre-Exposure Prophylaxis Against Francisella tularensis
-
批准号:8664795
-
项目类别:
-
资助金额:$70.67万
-
财政年份:2013
-
负责人:MARCUS AARON HORWITZ
-
依托单位:
Pre-Exposure Prophylaxis Against Francisella tularensis
-
批准号:8508014
-
项目类别:
-
资助金额:$70.91万
-
财政年份:2012
-
负责人:MARCUS AARON HORWITZ
-
依托单位:
海外基金